NASDAQ$MLAB

Mesa Laboratories Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Mesa Labs' financial performance saw revenue increase by 60%, but operating income decreased significantly due to unusual items. Net loss was also reported.

Mesa Labs reported a 60% increase in revenue for Q3 2022, driven by organic growth and acquisitions. However, the company experienced a decrease in operating income and reported a net loss, impacted by unusual items related to acquisitions and other adjustments.

  • Revenues increased by 60% compared to the same quarter last year, reaching $54,696 thousand.
  • Operating loss was $(2,512) thousand, a significant decrease compared to the prior year's operating income of $22 thousand.
  • Net loss was $(2,060) thousand, or $(0.39) per diluted share.
  • Organic revenue growth was 12% for the quarter.

Headline financials

Total Revenue

$54.7M

Previous: $34.2M+60.1%
EPS (adj)

$1.36

Previous: $1.46-6.8%
Capital Expenditures

-$3.65M

Previous: -$954K-282.6%
Free Cash Flow

$26.3M

Previous: $22.6M+16.2%
Net Income

-$2.06M

Previous: -$6.91M+70.2%
Operating Income

-$2.51M

Previous: $22K-11518.2%
Gross Profit

$28.6M

Previous: $20.7M+38.6%
Cash & Equivalents

$51.7M

Previous: $254M-79.6%
Total Assets

$722M

Previous: $622M+16.1%
Stock-Based Comp

$3.7M

Previous: $3.61M+2.5%

Revenue & EPS history

Mesa Labs · Revenue · Quarterly

$54.7M

Q3 2022+60.1%vs Q3 2021
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Revenue by segment

Mesa Labs · $54.8M total across 4 segments · Q3 2022

  • Clinical Genomics
    $16.5M
  • Sterilization and Disinfection Control
    $14.2M+9.5%
  • Biopharmaceutical Development
    $12.6M+44.4%
  • Calibration Solutions
    $11.5M

Forward guidance

Mesa Labs completed the acquisition of Agena Bioscience and anticipates continued organic revenue and profitability growth, despite ongoing pandemic-related headwinds, with the Mesa Way operating model.

Tailwinds

  • Double-digit organic revenues growth yielding 12% for the quarter.
  • Completed the acquisition of Agena Bioscience.
  • The Mesa Way operating model continues to build increasing resilience into our businesses.
  • Excited about Agena’s growth prospects and the strategic options it brings to our future.
  • The quality of our business portfolio improved during the quarter with the acquisition of Agena Bioscience.

Headwinds

  • Ongoing pandemic related headwinds including obstacles to direct customer engagement, supply chain reliability, and personnel availability.
  • Calibration Solutions continues to struggle with revenues contracting 6% in the quarter as compared to the prior year.
  • Global supply chain complications and pandemic related labor shortages.
  • Gross profit percentage shrank by 310 bps versus prior year in the quarter from lower volumes and higher labor costs.
  • Uncertainty to come.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+0.1%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-0.1%

Avg return

30 days after

55%

35 / 64 earnings

Positive

+26.6%

Q2 2023

Best reaction

-24.9%

Q1 2026

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026
Q3 2026+8.7%+15.9%+8.8%
Q2 2026+2.1%+6.7%+3.7%
Q1 2026-24.9%-16.0%-15.9%
Q4 2025-9.3%-13.5%-12.8%
Q3 2025+2.5%+10.3%+3.2%
Q2 2025-11.4%-16.2%-7.6%
Q1 2025+5.8%+11.8%+13.4%
Q4 2024+13.3%+5.5%-3.4%
Q3 2024+2.0%-0.2%+18.9%
Q2 2024+0.1%-8.8%+2.0%
Q1 2024+8.0%+10.3%+11.4%
Q4 2023-2.2%-7.7%-11.7%
Q3 2023-7.4%-8.6%-13.5%
Q2 2023+26.6%+31.2%+39.1%
Q1 2023-5.5%-10.7%-23.5%
Q4 2022-3.7%-2.7%-6.1%
Q3 2022-3.9%-2.0%-5.8%
Q2 2022+4.0%+1.4%-0.1%
Q1 2022+0.4%-1.4%-3.8%
Q4 2021+4.7%+6.4%+9.6%
Q3 2021+0.9%-0.4%-5.2%
Q2 2021-0.4%+2.7%+2.1%
Q1 2021+2.0%-1.5%-1.4%
Q4 2020-5.7%-6.5%-18.6%
Q3 2020-7.2%-2.4%-13.9%
Q2 2020-0.2%-4.7%+3.3%
Q1 2020+6.6%+7.0%-7.3%
Q4 2019-21.1%-19.3%-2.3%
Q3 2019+0.6%+3.4%+2.2%
Q2 2019+0.9%+3.0%+20.4%
Q1 2019-2.7%-0.3%+3.5%
Q4 2018+16.3%+15.4%+31.3%
Q3 2018-5.1%-14.2%-8.0%
Q2 2018-17.2%-19.7%-19.7%
Q1 2018+5.2%+1.6%-2.5%
Q4 2017-6.5%-13.3%-12.3%
Q3 2017+6.4%+1.4%+5.2%
Q2 2017-1.3%-0.8%-1.1%
Q1 2017-4.3%-10.4%-10.5%
Q4 2016+12.7%+26.5%+23.1%
Q3 2016-4.8%
Q2 2016+1.9%
Q1 2016+13.3%
Q4 2015+2.1%
Q3 2015+0.8%
Q2 2015+10.4%
Q1 2015-2.0%
Q4 2014-4.0%
Q3 2013-0.2%
Q3 2014-0.2%
Q2 2014-0.1%
Q1 2014-3.5%
Q4 2013-0.2%
Q2 2013-1.8%
Q1 2013-0.8%
Q4 2012+2.5%
Q3 2011+1.3%
Q3 2012+1.3%
Q2 2011+1.5%
Q2 2012+1.5%
Q4 2011+0.0%
Q1 2011+0.0%
Q1 2012+0.0%
Q4 2010+0.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro